The estimated Net Worth of Andrew C. Jackson is at least $418 mil dollars as of 20 November 2021. Mr Jackson owns over 2,684 units of Catheter Precision stock worth over $13,594 and over the last 5 years he sold RMED stock worth over $22,845. In addition, he makes $381,850 as Chief Financial Officer at Catheter Precision.
Mr has made over 4 trades of the Catheter Precision stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 2,684 units of RMED stock worth $7,032 on 20 November 2021.
The largest trade he's ever made was buying 10,000 units of Catheter Precision stock on 3 August 2020 worth over $3,500. On average, Mr trades about 2,782 units every 89 days since 2019. As of 20 November 2021 he still owns at least 23,041 units of Catheter Precision stock.
You can see the complete history of Mr Jackson stock trades at the bottom of the page.
Andrew C. Jackson is the Chief Financial Officer at Catheter Precision.
As the Chief Financial Officer of Catheter Precision, the total compensation of Mr Jackson at Catheter Precision is $381,850. There are 1 executives at Catheter Precision getting paid more, with Jonathan Will McGuire having the highest compensation of $536,125.
Mr Jackson is 52, he's been the Chief Financial Officer of Catheter Precision since . There are 1 older and no younger executives at Catheter Precision. The oldest executive at Catheter Precision Inc. is Jonathan Will McGuire, 58, who is the CEO & Director.
Andrew's mailing address filed with the SEC is C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD, CA, 92011.
Over the last 6 years, insiders at Catheter Precision have traded over $709,539 worth of Catheter Precision stock and bought 199,373 units worth $197,741 . The most active insiders traders include Jeffrey J Kraws, Jonathan Will Mc Guire y Dean Burstein Melissa Dean .... On average, Catheter Precision executives and independent directors trade stock every 34 days with the average trade being worth of $12,983. The most recent stock trade was executed by Andrew C. Jackson on 20 November 2021, trading 2,684 units of RMED stock currently worth $7,032.
advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of
Catheter Precision executives and other stock owners filed with the SEC include: